Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
Fig 6
Synergy between PKC agonists and HDACi’s.
(A) The fraction of cells reactivated, fon predicted by our simulations for different values of ϕPKCa and ϕHDACi, the fold-increase in the rate of NF-κB synthesis and HIV-1 transcription due to a PKC agonist and an HDACi, respectively. The lines are contours of constant fon. (B) The corresponding synergy between the drugs, β, predicted using Eqs (19)–(21). The maximum synergy is indicated.